Peptide Hormone Or Derivative Utilizing Patents (Class 514/5.3)
-
Publication number: 20130085100Abstract: The present invention is directed to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful for the treatment of a disorder selected from obesity and insulin resistance and related methods and pharmaceutical formulations. In particular, the invention relates to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful in the treatment of metabolic syndrome.Type: ApplicationFiled: May 17, 2011Publication date: April 4, 2013Applicant: UNIVERSITÉ DE GENÈVEInventors: Françoise Rohner-Jeanrenaud, Nicolas Deblon
-
Publication number: 20130085099Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistence in the body, solubility, and bioavailability.Type: ApplicationFiled: June 15, 2012Publication date: April 4, 2013Applicant: DUKE UNIVERSITYInventor: Ashutosh Chilkoti
-
Publication number: 20130079277Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.Type: ApplicationFiled: April 13, 2012Publication date: March 28, 2013Applicant: DUKE UNIVERSITYInventor: Ashutosh Chilkoti
-
Publication number: 20130079278Abstract: The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: September 21, 2012Publication date: March 28, 2013Applicant: NOVO NORDISK A/SInventor: Novo Nordisk A/S
-
Publication number: 20130072427Abstract: Compounds of formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.Type: ApplicationFiled: July 22, 2010Publication date: March 21, 2013Inventors: Cristiano Guimaraes, Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
-
Publication number: 20130053304Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.Type: ApplicationFiled: April 29, 2011Publication date: February 28, 2013Inventors: Yinxiang Wang, Fenlai Tan, Shaojing Hu, Xiangdong Zhao, Cunbo Ma, Yanping Wang, Xiaoyan Shen, Lieming Ding, Yunyan Hu, Hong Cao, Wei Long
-
Publication number: 20130053307Abstract: Methods are provided for increased rates of weight loss while reducing the discomfort caused by dieting. An initial daily dose of HCG of 200 IU or greater is administered to a patient on a reduced calorie diet plan for weight loss. The reduced calorie diet plan includes limits on the amounts of protein, vegetables and fruits that may be eaten based upon caloric content and sugar levels in the vegetables and fruit. In one embodiment, the reduced calorie diet plan limits caloric intake to 500-800 calories per day. The patient is monitored and the daily HCG dose may be adjusted upward as needed to control hunger and maintain patient comfort.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Inventor: Sherri L. Emma
-
Patent number: 8372804Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.Type: GrantFiled: October 24, 2008Date of Patent: February 12, 2013Assignee: MannKind CorporationInventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
-
Publication number: 20130035281Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.Type: ApplicationFiled: February 7, 2012Publication date: February 7, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas Klein, Rolf Grempler, Michael Mark
-
Publication number: 20130034535Abstract: Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.Type: ApplicationFiled: August 13, 2012Publication date: February 7, 2013Applicant: PIVOTAL THERAPEUTICS INC.Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar SHAIKH, Jason YANTHA, Valerie SCHINI-KERTH
-
Publication number: 20130035285Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.Type: ApplicationFiled: March 28, 2011Publication date: February 7, 2013Applicant: Novo Nordisk A/SInventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl
-
Patent number: 8367607Abstract: The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.Type: GrantFiled: December 15, 2010Date of Patent: February 5, 2013Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Wayne David Kohn
-
Publication number: 20130023464Abstract: Peptide analogues of PYY, compositions comprising said analogues and methods of using said analogues for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for a reduction in appetite, reduction in food intake or reduction of calorie intake in a subject.Type: ApplicationFiled: January 27, 2011Publication date: January 24, 2013Inventor: Stephen Robert Bloom
-
Publication number: 20130023467Abstract: The present invention refers to a pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.Type: ApplicationFiled: May 9, 2012Publication date: January 24, 2013Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
-
Patent number: 8354370Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: GrantFiled: June 16, 2008Date of Patent: January 15, 2013Assignee: Garnet BioTherapeutics, Inc.Inventors: Gene Kopen, Joseph Wagner, Vanessa Ragaglia, Baron Heimbach, Richard S. Gore
-
Publication number: 20130012427Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: June 8, 2012Publication date: January 10, 2013Applicant: NOVO NORDISK A/SInventors: LAUGE SCHAEFFER, THOMAS KRUSE, HENNING THOEGERSEN
-
Publication number: 20130011361Abstract: The present invention provides heterocyclic derivatives of formula (I) that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: October 1, 2010Publication date: January 10, 2013Applicants: XENON PHARMACEUTICALS INC., NOVARTIS AGInventors: Natalie Dales, Jianmin Fu, Qi Jia, Natalia Pokrovskaia, Shaoyi Sun, Zaihui Zhang
-
Publication number: 20130005649Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.Type: ApplicationFiled: May 9, 2012Publication date: January 3, 2013Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Elisabeth NIEMÖELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
-
Publication number: 20130005646Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: June 8, 2012Publication date: January 3, 2013Applicant: Novo Nordisk A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Publication number: 20120329708Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: December 27, 2012Applicant: Indiana University Research and Technology CorporationInventors: Richard D. DiMARCHI, David L. SMILEY
-
Publication number: 20120329707Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: December 27, 2012Applicant: Indiana University Research and Technology CorporationInventors: Richard D. DiMARCHI, David L. SMILEY, Bin YANG
-
Publication number: 20120295845Abstract: Compounds of formula (I) wherein: X is (A) or (B); Y is O or a bond; R1 is —C(O)—O—R3 or R2 is hydrogen, cyano, C1-C6 alkyl, or C3-C6 cycloalkyl; R5 is hydrogen, cyano, nitro, C1-C6 fluoroalkyl, C1-C6 alkyl, C1-C6 alkoxy, fluoroalkoxy, or C3-C6 cycloalkyl; R6 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, —C(O)—NH2, or C1-C6 alkyl substituted with hydroxy or C1-C6 alkoxy; m is 1 or 2, wherein when m is 1 then R8 is hydrogen, C1-C6 alkyl, —CH2—(C1-C5)haloalkyl, C3-C6 cycloalkyl, or C1-C6 alkyl substituted with hydroxy; and when m is 2 then each R8 is independently C1-C3 alkyl or —CH2—(C1—C2)haloalkyl; modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.Type: ApplicationFiled: November 16, 2010Publication date: November 22, 2012Inventors: Vincent Mascitti, Kim F. McClure, Michael J. Munchhof, Ralph P. Robinson
-
Publication number: 20120288511Abstract: Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-I receptor, or activity at each of the glucagon receptor and the GLP-I receptor. In some embodiments, the glucagon analog exhibits at least 100% or more of the activity of native glucagon at the glucagon receptor and/or at least 100% or more of the activity of native GLP-I at the GLP-I receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is within 50-fold or less than the EC50 at the glucagon receptor. In some embodiments, the glucagon analog has an EC50 at the GLP-I receptor which is two- to ten-fold greater than the EC50 at the glucagon receptor. Related conjugates, dimers and multimers, and pharmaceutical compositions, and uses thereof, are further provided.Type: ApplicationFiled: December 9, 2010Publication date: November 15, 2012Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventor: Richard D. Dimarchi
-
Publication number: 20120289453Abstract: Novel GLP-1 compounds and their therapeutic use.Type: ApplicationFiled: May 16, 2012Publication date: November 15, 2012Applicant: Novo Nordisk A/SInventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
-
Publication number: 20120283169Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.Type: ApplicationFiled: November 2, 2011Publication date: November 8, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Rolf GREMPLER, Odd-Eric JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
-
Publication number: 20120283179Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.Type: ApplicationFiled: November 11, 2010Publication date: November 8, 2012Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Anette Brunner-Schwarz, Werner Mueller, Verena Siefke-Henzler
-
Publication number: 20120277147Abstract: A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.Type: ApplicationFiled: March 28, 2012Publication date: November 1, 2012Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Gabor BOKA, Louise SILVESTRE, Patrick MIOSSEC
-
Patent number: 8299022Abstract: The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below: (R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 wherein the definitions of A1 to A28, R1 and R2 are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said compound together with therapeutic and non-therapeutic uses thereof.Type: GrantFiled: September 24, 2007Date of Patent: October 30, 2012Assignee: IPSEN Pharma S.A.S.Inventor: Zheng Xin Dong
-
Patent number: 8288343Abstract: The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.Type: GrantFiled: March 28, 2008Date of Patent: October 16, 2012Assignee: National University Corporation Nagoya UniversityInventors: Mitsuru Horiba, Kenji Kadomatsu, Itsuo Kodama, Takashi Muramatsu, Hisaaki Ishiguro, Hiroharu Takenaka, Arihiro Sumida
-
Patent number: 8283311Abstract: A safe and widely-applicable food intake regulator can be provided by using at least one peptide selected from the group consisting of a fish or mammalian melanin-concentrating hormone (MCH) and enzymatic digests thereof, which have the activity to suppress food intake.Type: GrantFiled: March 3, 2009Date of Patent: October 9, 2012Assignee: Maruha Nichiro Foods, Inc.Inventors: Hiroyuki Enari, Motohiko Tada, Yoshinori Takahashi, Masataka Kawarasaki
-
Publication number: 20120245083Abstract: Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments.Type: ApplicationFiled: October 27, 2010Publication date: September 27, 2012Applicant: Novo Nordisk A/SInventors: Anette Sams Nielsen, Thomas Kruse, Janos Tibor Kodra, Jesper F. Lau, Jacob Kofoed, Kirsten Raun, Cecilia Nilsson
-
Publication number: 20120238493Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.Type: ApplicationFiled: December 20, 2011Publication date: September 20, 2012Inventors: Richard D. DiMARCHI, Brian P. WARD
-
Patent number: 8258094Abstract: The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: (R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A-26-A27-A28-R1 wherein the definitions of A1 to A28 and R1 to R3 are provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.Type: GrantFiled: March 28, 2008Date of Patent: September 4, 2012Assignee: IPSEN Pharma S.A.S.Inventors: Zheng Xin Dong, Michael DeWitt Culler, Yeelana Shen, Jeanne Mary Comstock
-
Publication number: 20120196799Abstract: Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent. Additionally, methods for reducing insulin-induced weight gain are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist.Type: ApplicationFiled: April 12, 2012Publication date: August 2, 2012Applicant: Amylin Pharmaceuticals, Inc.Inventors: Bradford J. DUFT, Orville G. Kolterman
-
Publication number: 20120196798Abstract: This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.Type: ApplicationFiled: January 31, 2012Publication date: August 2, 2012Inventors: Yali Wang, Aifeng Lü, Changan Sun, Hengli Yuan
-
Publication number: 20120190616Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.Type: ApplicationFiled: July 22, 2010Publication date: July 26, 2012Applicant: IPSEN PHARMA S.A.S.Inventors: Zheng Xin Dong, Nicholas C. Prairie, Maria L. Ufret, Jundong Zhang, Deborah M. Rothman, Jeanne Mary Comstock
-
Publication number: 20120183616Abstract: The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.Type: ApplicationFiled: July 30, 2010Publication date: July 19, 2012Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Kennett Sprogoe, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Harald Rau, Thomas Wegge
-
Publication number: 20120184486Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).Type: ApplicationFiled: October 21, 2010Publication date: July 19, 2012Inventor: Vincent Mascitti
-
Publication number: 20120178670Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: June 24, 2010Publication date: July 12, 2012Applicant: Zealand Pharma A/SInventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
-
Publication number: 20120172295Abstract: Glucagon peptides with increased GIP activity are provided, optionally with GLP-I and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.Type: ApplicationFiled: June 16, 2010Publication date: July 5, 2012Applicant: Indiana University Research And Technology CorpInventors: Richard D. Dimarchi, David L. Smiley, Maria Dimarchi, Joseph Chabenne, Jonathan Day, James Patterson, Brian P. Ward, Tao Ma
-
Publication number: 20120142582Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.Type: ApplicationFiled: June 7, 2010Publication date: June 7, 2012Inventor: Anthony H. Cincotta
-
Publication number: 20120141448Abstract: Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.Type: ApplicationFiled: November 23, 2011Publication date: June 7, 2012Inventors: Lorenzo De Ferra, Marvin Heuer, Scott Hagerman, Martin Purpura, Ralf Jäger
-
Publication number: 20120129767Abstract: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.Type: ApplicationFiled: November 2, 2011Publication date: May 24, 2012Inventors: Giovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
-
Publication number: 20120129768Abstract: This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.Type: ApplicationFiled: July 29, 2010Publication date: May 24, 2012Inventors: Yali Wang, Aifeng Lü, Changan Sun, Hengli Yuan
-
Patent number: 8183203Abstract: A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest, bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity, or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can be delivered. A method for the treatment of cardiac arrest or pulmonary hypertension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention.Type: GrantFiled: September 25, 2009Date of Patent: May 22, 2012Assignee: Avant Garde Therapeutics & Technologies LLCInventor: Leo Rubin
-
Publication number: 20120115777Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: ApplicationFiled: January 17, 2012Publication date: May 10, 2012Applicant: MANNKIND CORPORATIONInventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
-
Publication number: 20120114588Abstract: The present invention regards specific IBAT inhibitors with improved effect in prophylaxis and treatment of metabolic syndrome, obesity, disorders of fatty acid metabolism, glucose utilization disorders, disorders in which insulin resistance is involved, diabetes mellitus, type 1 and type 2 diabetes. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.Type: ApplicationFiled: May 26, 2011Publication date: May 10, 2012Applicant: ALBIREO ABInventors: Ingemar Starke, Hans Graffner, Per-Göran Gillberg, Ann-Margret Lindqvist, Bo Angelin
-
Publication number: 20120115778Abstract: Methods for treating eating disorders associated with excessive weight gain, suppressing appetite, reducing body weight, or treating obesity in an animal by administering one or more antagonists of the serotonin Htr1a or Htr2b receptor, or a Tph2 inhibitor are provided, or combinations thereof.Type: ApplicationFiled: July 15, 2010Publication date: May 10, 2012Applicant: The Trustees of Columbia University in the City of New YorkInventors: Gerard Karsenty, Vijay Yadav, Franck Oury
-
Publication number: 20120094894Abstract: The invention relates to antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia, inter alia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. The medication is a mono treatment with a DPP-4 inhibitor <preferably linagliptin> or a combination treatment with a DPP-4 inhibitor and a second and/or third antidiabetic.Type: ApplicationFiled: February 12, 2010Publication date: April 19, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Eva Ulrike Graefe-Mody, Hans-Juergen Woerle
-
Patent number: 8158582Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. The invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) effective to improve metabolism in the patient, where the patient receives IGF-1 in a single daily administration.Type: GrantFiled: June 1, 2006Date of Patent: April 17, 2012Assignee: Tercica, Inc.Inventors: Ross G. Clark, Gillian Clark, legal representative